Bharat Parenterals Intrinsic Value
Bharat Parenterals (BPLPHARMA) median intrinsic value is ₹612.68 from 5 valuation models (range ₹460–₹969), vs current price ₹1531.70 — -60.0% downside (Trading Above Calculated Value), margin of safety -100.0%. Check BPLPHARMA company valuation to track the company's total market size over time.
BPLPHARMA Valuation Methods Summary — DCF, Graham Number & P/E
Bharat Parenterals intrinsic value across 5 models vs current price ₹1531.70 — upside/downside and value range per method. For current market price and key ratios, visit BPLPHARMA share price screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹968.57 | ₹871.71 - ₹1065.43 | -36.8% | Book Value/Share: ₹484.29, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹777.14 | ₹699.43 - ₹854.85 | -49.3% | Revenue/Share: ₹388.57, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹612.68 | ₹551.41 - ₹673.95 | -60.0% | EBITDA: ₹16.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹612.68 | ₹490.14 - ₹735.22 | -60.0% | CF Growth: 5.0%, Discount: 15% |
| Dividend Yield Method | dividend | ₹459.51 | ₹413.56 - ₹505.46 | -70.0% | DPS: ₹1.00, Target Yield: 2.5% |
BPLPHARMA Intrinsic Value vs Market Price — All Valuation Models
Bharat Parenterals fair value range ₹460–₹969 vs current market price ₹1531.70 across 5 valuation models. See BPLPHARMA price book multiple to compare market price against book value per share.
BPLPHARMA Intrinsic Value Analysis — Undervalued or Overvalued?
Bharat Parenterals median intrinsic value ₹612.68, current price ₹1531.70 — Trading Above Calculated Value by 60.0%, margin of safety -100.0%.
What is the intrinsic value of BPLPHARMA?
Based on our comprehensive analysis using 5 different valuation methods, the estimated intrinsic value of Bharat Parenterals (BPLPHARMA) is ₹612.68 (median value). With the current market price of ₹1531.70, this represents a -60.0% variance from our estimated fair value.
The valuation range spans from ₹459.51 to ₹968.57, indicating ₹459.51 - ₹968.57.
Is BPLPHARMA undervalued or overvalued?
Based on our multi-method analysis, Bharat Parenterals (BPLPHARMA) appears to be trading above calculated value by approximately 60.0%.
BPLPHARMA Financial Health — Key Ratios vs Industry Benchmarks
Bharat Parenterals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 3.96 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.91 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | -10.6% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 1.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.42x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
BPLPHARMA Cash Flow Quality — Operating & Free Cash Flow
Bharat Parenterals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-27 Cr | ₹-96 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-5 Cr | ₹-58 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹22 Cr | ₹-17 Cr | Positive Operating Cash Flow | 6/10 |
| March 2022 | ₹-1 Cr | ₹-5 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹25 Cr | ₹4 Cr | Positive Free Cash Flow | 7/10 |